Head-To-Head Review: TearLab (OTCMKTS:TEAR) and PAVmed (NASDAQ:PAVM)

TearLab (OTCMKTS:TEAR) and PAVmed (NASDAQ:PAVM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Insider & Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. 5.2% of TearLab shares are owned by company insiders. Comparatively, 7.3% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for TearLab and PAVmed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TearLab	0	0	0	0	0.00
PAVmed	0	0	1	0	3.00

PAVmed has a consensus target price of $19.00, suggesting a potential upside of 3,511.48%. Given PAVmed’s stronger consensus rating and higher probable upside, analysts plainly believe PAVmed is more favorable than TearLab.

Valuation & Earnings

This table compares TearLab and PAVmed”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TearLab	N/A	N/A	N/A	N/A	N/A
PAVmed	$2.99 million	3.01	$39.79 million	$0.71	0.74

PAVmed has higher revenue and earnings than TearLab.

Profitability

This table compares TearLab and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TearLab	N/A	N/A	N/A
PAVmed	3,711.54%	N/A	-42.29%

Summary

PAVmed beats TearLab on 7 of the 8 factors compared between the two stocks.

About TearLab

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.